Semaglutide found to cut major adverse cardiovascular events in people with overweight, obesity

Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published online June 22 in Diabetes Care. Ildiko Lingvay, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues randomly assigned people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes to weekly semaglutide 2.4 mg or placebo to examine the cardiovascular effects of semaglutide. Outcomes, including first major adverse cardiovascular event (MACE), which included cardiovascular mortality, nonfatal myocardial infarction, or Read More

Related posts:

  1. New biomarker identified for predicting adverse events of tuberculosis therapy
  2. Researchers find adverse drug events are frequent and many are preventable in the outpatient setting
  3. HMN: Overweight and obesity Statistics 2025
  4. Discovery could help reduce adverse side effects of popular next-generation obesity medications
  5. Routine ECG screening may help to prevent cardiovascular disease events in adults
  6. Team discovers why people who lack a specific blood group are genetically predisposed to be overweight or obese
  7. Study finds major hearing difficulties in people over 90
  8. Major trial looks at most effective speech therapy for people with Parkinson’s disease

Leave a Reply

Your email address will not be published. Required fields are marked *